scispace - formally typeset
D

Dietmar Herndler-Brandstetter

Researcher at Yale University

Publications -  54
Citations -  3665

Dietmar Herndler-Brandstetter is an academic researcher from Yale University. The author has contributed to research in topics: Immune system & T cell. The author has an hindex of 26, co-authored 49 publications receiving 3168 citations. Previous affiliations of Dietmar Herndler-Brandstetter include Austrian Academy of Sciences & University of Innsbruck.

Papers
More filters
Journal ArticleDOI

Biology of immune responses to vaccines in elderly persons.

TL;DR: Improved vaccination strategies, new adjuvants, and new vaccines that specifically target the aged immune system will help to overcome the limitations of immunosenescence and ensure a better protection of the vulnerable elderly population.
Journal ArticleDOI

Long-Term Cytomegalovirus Infection Leads to Significant Changes in the Composition of the CD8 T-Cell Repertoire, Which May Be the Basis for an Imbalance in the Cytokine Production Profile in Elderly Persons

TL;DR: It is demonstrated that aging as well as CMV infection lead to a decrease in the size of the naïve and the early memory T-cell pool but to an increase in the number of CD8+ effector T cells, which produce gamma interferon but lack substantial growth potential.
Journal ArticleDOI

KLRG1+ Effector CD8+ T Cells Lose KLRG1, Differentiate into All Memory T Cell Lineages, and Convey Enhanced Protective Immunity.

TL;DR: It is demonstrated that developmental plasticity of KLRG1+ effector CD8+ T cells is important in promoting functionally versatile memory cells and long‐term protective immunity and drives functional diversity within memory T cell lineages and promotes enhanced anti‐influenza and anti‐tumor immunity.
Journal ArticleDOI

Anti-SIRPα antibody immunotherapy enhances neutrophil and macrophage antitumor activity.

TL;DR: An anti-human SIRPα antibody, KWAR23, is developed, which in combination with tumor-opsonizing antibodies, greatly augmented neutrophil and macrophage antitumor activity in vitro and in vivo and may represent a promising candidate for combination therapies.